Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldopam.
Kini
Annapoorna S
AS
Cardiac Catheterization Laboratory of the Cardiovascular Institute, Mount Sinai School of Medicine, New York, New York, USA.
Mitre
Cristina A
CA
Kamran
Mazullah
M
Suleman
Javed
J
Kim
Michael
M
Duffy
Mary E
ME
Marmur
Jonathan D
JD
Sharma
Samin K
SK
D000368:Aged; D017225:Atherectomy, Coronary; D006328:Cardiac Catheterization; D003287:Contrast Media / Q000009:adverse effects*; D003928:Diabetic Nephropathies / Q000150:complications*; D018491:Dopamine Agonists / Q000627:therapeutic use*; D005260:Female; D018818:Fenoldopam / Q000627:therapeutic use*; D006801:Humans; D015994:Incidence; D007674:Kidney Diseases / Q000139:chemically induced* / Q000517:prevention & control; D007676:Kidney Failure, Chronic / Q000150:complications*; D008297:Male; D012307:Risk Factors; D015607:Stents; D014283:Triiodobenzoic Acids / Q000009:adverse effects*
D003287:Contrast Media; D018491:Dopamine Agonists; D014283:Triiodobenzoic Acids; D018818:Fenoldopam; C054871:ioversol